Merck Pursues $6 Billion Acquisition of Terns Pharma, Reports FT

Merck & Co. is reportedly finalizing a deal to acquire Terns Pharma for approximately $6 billion. This acquisition may influence market dynamics in the biotech sector, as Merck aims to expand its product portfolio. The completion of this deal could affect Merck's stock performance and investor sentiment towards its future growth trajectory. No specific trading volumes or stock price changes were provided in relation to this news.

Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.